IfPA’s Patient Access Policy Blog

Orphan Drug Access Still Eludes Some Cystic Fibrosis Patients

More than a year after a breakthrough drug for cystic fibrosis became available, fewer than half of patients who meet the Food and Drug Administration’s

Read More

IfPA White Paper Explores Access to Emerging Treatments for Alzheimer’s, Parkinson’s

Millions of Americans and their families struggle every day with the devastating effects of Alzheimer’s, Parkinson’s and Huntington’s diseases.   They remain hopeful for treatments that

Read More

IfPA Cautions ICER against “Discriminating” Among Psoriasis Treatments

Evaluating cost effectiveness is one thing; using value assessments to rank patients’ treatment options is quite another. Yet that’s precisely what the Institute for Clinical

Read More

WHO Meeting Looks Forward on Distinguishable Names

By: Brian Kennedy, Executive Director, Global Alliance for Patient Access This month’s World Health Organization Open Sessions with INN Stakeholders explored the value, and the

Read More

Awareness Month Highlights Breast Cancer Disparities & Access Challenges

Breast Cancer Awareness Month, celebrated this October, invites public dialogue about screening, risk factors and the value of early detection. But it may also present

Read More

NCfIH Marks RSV Awareness Month with Release of New “Fast Facts”

October marks the beginning of both the RSV viral season and RSV awareness month. The National Coalition for Infant Health is taking the opportunity to

Read More

Nordic Patient Groups Tackle Biosimilar Policy Issues

Biosimilar medicines are being prescribed more and more freely across Europe. But access to, and use of, these new medicines differs greatly depending on which

Read More

New IfPA Data Support Non-Medical Switching Concerns

Preliminary data from the Institute for Patient Access suggest what opponents of non-medical switching have long suspected: having medications switched for financial reasons could be

Read More

New Report: Biosimilar Cost Savings Won’t Reach Patients

Since the advent of biosimilars, experts and pundits have debated how reduced biosimilar prices will be and just much savings the follow-on drugs will offer.

Read More

Are New Cancer Meds Worth Their Cost?

Innovative but costly anti-cancer drugs have spurred the development of several value assessments and cost frameworks, all designed to explore one question: Do the benefits

Read More
Back to Top